US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iPath Select MLP ETN

33.75

-0.7612-2.21%

Post-market: 33.750.00000.00%16:10 EDT

Volume:16.91K

Turnover:575.31K

Market Cap:630.03M

PE:- -

High:34.14

Open:34.13

Low:33.75

Close:34.51

52wk High:36.81

52wk Low:27.23

Shares:18.67M

Float Shares:18.67M

Volume Ratio:1.06

T/O Rate:0.09%

Dividend:1.55

Dividend Rate:4.59%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial

Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATMP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","market":"US","secType":"STK","nameCN":"iPath Select MLP ETN","latestPrice":33.75,"timestamp":1780084800000,"preClose":34.51118,"halted":0,"volume":16909,"hourTrading":{"tag":"盘后","latestPrice":33.75,"preClose":33.75,"latestTime":"16:10 EDT","volume":8,"amount":270,"timestamp":1780085404312,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.022056040969911865,"floatShares":18667506,"shares":18667506,"eps":0,"marketStatus":"Market Closed","change":-0.76118,"latestTime":"05-29 16:00:00 EDT","open":34.13,"high":34.14,"low":33.75,"amount":575308,"amplitude":0.011301,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":34.51118,"sharesOutstanding":18317506,"nav":34.98,"aum":652989359.88,"dividendRate":0.045938,"bidAskSpread":0.001495,"postHourTrading":{"tag":"盘后","latestPrice":33.75,"preClose":33.75,"latestTime":"16:10 EDT","volume":8,"amount":270,"timestamp":1780085404312,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.06251,"impliedVol":0.0544,"impliedVolPercentile":0.243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","floatShares":18667506,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.06251,"shares":18667506,"dividePrice":1.5504,"high":34.14,"amplitude":0.011301,"preClose":34.51118,"low":33.75,"week52Low":27.23,"pbRate":"--","week52High":36.81,"institutionHeld":0,"latestPrice":33.75,"eps":0,"divideRate":0.045938,"volume":16909,"delay":0,"ttmEps":0,"open":34.13,"prevYearClose":28.77,"prevWeekClose":36.6116,"prevMonthClose":35.4,"prevQuarterClose":34.4097,"fiveDayClose":36.29,"twentyDayClose":35.4,"sixtyDayClose":34.0487},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATMP\",params:#limit:5,,,undefined,":[{"date":"2026-05-29","symbol":"ATMP","amount":0.40882,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-29","defaultRemindTime":1780061400000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-08","payableDate":"2026-05-29","currency":"USD","dateTimestamp":1780027200000,"payDate":"2026-06-08"},{"date":"2026-03-02","symbol":"ATMP","amount":0.392948056,"announcedDate":"2026-02-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-02","defaultRemindTime":1772461800000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-10","payableDate":"2026-03-02","currency":"USD","dateTimestamp":1772427600000,"payDate":"2026-03-10"},{"date":"2025-12-01","symbol":"ATMP","amount":0.39806809,"announcedDate":"2025-11-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-01","defaultRemindTime":1764599400000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-09","payableDate":"2025-12-01","currency":"USD","dateTimestamp":1764565200000,"payDate":"2025-12-09"},{"date":"2025-08-28","symbol":"ATMP","amount":0.381190999,"announcedDate":"2025-08-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-28","defaultRemindTime":1756387800000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-08","payableDate":"2025-08-28","currency":"USD","dateTimestamp":1756353600000,"payDate":"2025-09-08"},{"date":"2025-05-29","symbol":"ATMP","amount":0.380144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-29","defaultRemindTime":1748525400000,"name":"iPath Select MLP ETN","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-06","payableDate":"2025-05-29","currency":"USD","dateTimestamp":1748491200000,"payDate":"2025-06-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATMP\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-27","recordDate":null,"paymentDate":null,"value":0.2845092,"currency":"USD"},{"executeDate":"2017-05-24","recordDate":null,"paymentDate":null,"value":0.2714382,"currency":"USD"},{"executeDate":"2017-08-24","recordDate":null,"paymentDate":null,"value":0.302208,"currency":"USD"},{"executeDate":"2017-11-28","recordDate":null,"paymentDate":null,"value":0.2959505,"currency":"USD"},{"executeDate":"2018-02-28","recordDate":null,"paymentDate":null,"value":0.2574755,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATMP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6111,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1777435200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATMP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629727041","title":"Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629727041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629727041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:00","pubTimestamp":1776862800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today anno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3279030/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentation-of-HOPE-3-Phase-3-Results-at-the-American-Academy-of-Neurology-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","AFG","BK4211","CAPR","AAN","EMA","BK4178","HOPE","BK4081","BK4107","ATMP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622639022","title":"VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622639022","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622639022?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:19","pubTimestamp":1774433940,"startTime":"0","endTime":"0","summary":"Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028. A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment. Fully biological transplant eliminates need for immunosuppression and restores natural function. CVI market projected to reach USD 5,951 million by 2034*. Supported by USD 10 million financing from existing investors. GOTHENBURG, Sweden, March 25, 2026 /PRNewswire/ -- VERIGRAFT, a Swedish clinical-stage biotechnology company pioneering personalized, fully biological therapies, today announced the initiation of a pivotal Phase II/III trial of its P-TEV  in patients with chronic venous insufficiency , supported by USD 10 million from existing investors.The milestone comes at a time when regenerative medicine and personalized biologics are gaining significant traction among global investors and healthcare systems.Restorative effect of replacing diseased vein with fu","market":"us","thumbnail":"https://mma.prnewswire.com/media/2942028/VERIGRAFT_P_TEV.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2942028/VERIGRAFT_P_TEV.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/verigraft-advances-first-potential-curative-treatment-for-cvi-into-pivotal-phase-iiiii-trial-302724707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PI","BK4134","BK4138","III","CVI","LU1878469433.USD","ATMP","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620896241","title":"Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China","url":"https://stock-news.laohu8.com/highlight/detail?id=2620896241","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620896241?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:27","pubTimestamp":1773916020,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed  today announced that BBM-H901 , has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patients with moderate to severe hemophilia B . This product is developed and manufactured by BBM, and Takeda China is responsible for its commercialization in mainland China, Hong Kong, China and Macao, China. Following its approval in mainland China in April 2025 as the country's first gene therapy for hemophilia B, [1] the recent approval of BBM-H901 in Macao, China, not only addresses the previously unmet medical need for such treatment in the region but also marks a crucial step in accelerating the global availability of this breakthrough gene therapy.BBM-H901 is a gene therapy drug based on a recombinant adeno-associated virus  vector. It can precisely deliver the high-activity FIX gene into the liver cells of patients, enabling the sustained and h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-announced-bbm-h901-dalnacogene-ponparvovec-injection-chinas-first-hemophilia-b-gene-therapy-was-officially-approved-in-macao-china-302718633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","BK7504","ABR.AU","IE0009354923.USD","BK4183","EMA","BK4109","LU0054578231.USD","ABR","LU2463526074.USD","ASH.AU","LU0963586101.USD","ATMP","ASH","BK7057","BK4110","FIX","BK4081","BK4567","ODD","LU0053671581.USD","BLA.AU","BK4129","EMA.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618956571","title":"Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2618956571","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618956571?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:25","pubTimestamp":1773149100,"startTime":"0","endTime":"0","summary":"Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, inc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252978/0/en/Capricor-Therapeutics-Announces-Establishment-of-New-PDUFA-Date-for-Deramiocel-BLA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","ATMP","LABU","EMA","BK4588","BK4585","BK4139","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATMP\",params:#limit:6,delay:false,,,undefined,":[]}}